Key Points
- Director Christoph Samuel Ziegler purchased 30,000 Veraxa Biotech shares at an average price of $1.09, investing $32,700. His stake increased 378.21% to 37,932 shares.
- VRXA opened at $1.06 and was reported trading up 5.0%, while its 52-week range spans from $0.99 to $27.36.
- Wall Street Zen recently upgraded Veraxa Biotech from “sell” to “hold.” The company develops antibody-based cancer therapies, including antibody-drug conjugates and bispecific antibody candidates.
Veraxa Biotech Holding AG (NASDAQ:VRXA - Get Free Report) Director Christoph Samuel Ziegler purchased 30,000 shares of the company's stock in a transaction that occurred on Tuesday, October 20th. The shares were acquired at an average price of $1.09 per share, for a total transaction of $32,700.00. Following the completion of the acquisition, the director directly owned 37,932 shares of the company's stock, valued at $41,345.88. This trade represents a 378.21% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Veraxa Biotech Trading Up 5.0%
VRXA stock opened at $1.06 on Thursday. Veraxa Biotech Holding AG has a 1-year low of $0.99 and a 1-year high of $27.36.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen upgraded Veraxa Biotech from a "sell" rating to a "hold" rating in a research note on Monday, August 31st.
Get Our Latest Research Report on Veraxa Biotech
About Veraxa Biotech
(
Get Free Report)
VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
